At Cycle 1, 599 patients (41.8%) received prophylactic G-CSF for neutropenia, 95 patients (6.6%) received therapeutic G-CSF and 78 patients (5.4%) received both a prophylactic and therapeutic dose (Table 3). This evidence concerns the gene CSF3 and neutropenia.